logo
Twitter
Discord
Email
logo
logo
Harmony Biosciences Holdings, Inc.NASDAQ - HRMY
Reports
Search reports
Name
Reporting Date
Filing Date
2024-09-30 10-Q2024-09-302024-10-29
2024-06-30 10-Q2024-06-302024-08-06
2024-03-31 10-Q2024-03-312024-04-30
2023-12-31 10-K2023-12-312024-02-28
2023-12-31 10-K2023-12-312024-02-22
2023-09-30 10-Q2023-09-302023-10-31
2023-06-30 10-Q2023-06-302023-08-01
2023-03-31 10-Q2023-03-312023-05-02
2022-12-31 10-K2022-12-312023-02-21
2022-09-30 10-Q2022-09-302022-11-01
2022-06-30 10-Q2022-06-302022-08-02
2022-03-31 10-Q2022-03-312022-05-03
2021-12-31 10-K2021-12-312022-02-28
2021-09-30 10-Q2021-09-302021-11-09
2021-06-30 10-Q2021-06-302021-08-10
2021-03-31 10-Q2021-03-312021-05-11
2020-12-31 10-K2020-12-312021-03-25
2020-09-30 10-Q2020-09-302020-11-12
1
20 / page
About
Name
Harmony Biosciences Holdings, Inc.
Overview
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Show More
CEO
Mr. Jeffrey S. Aronin
Industry
Biotechnology
Exchange
NASDAQ
Listing Date
2020-08-19
Address
630 West Germantown Pike, Suite 215, Plymouth Meeting, PA, 19462, United States
Tel
484-539-9800
Website
https://www.harmonybiosciences.com